Alto Neuroscience Inc. (ANRO) Stock
Key stats
- Market cap
- $1.25B
- Price / Earnings ratio
- -13.3x
- EPS (TTM)
- -$2.42
- Volume
- Loading
- 52-week high
- $37.48
- 52-week low
- $10.80
Source: third-party data provider, as of November 13, 2026
Compare with ANRO
Recent news

Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
ANRO

Here's Why You Should Add ANRO Stock to Your Portfolio Now
Here's Why You Should Add ANRO Stock to Your Portfolio Now
ANRO

Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
ANRO

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
ANRO
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 71.06
- MACD 12/26/9
- 0.56
- EMA 9 of MACD
- -0.55
- MACD histogram
- 1.11
- SMA 50
- $26.62
- Price above SMA 50
- EMA 50
- $25.88
- Price above EMA 50
- SMA 200
- $24.59
- Price above SMA 200
- EMA 200
- $23.60
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
ANRO

Here's Why You Should Add ANRO Stock to Your Portfolio Now
Here's Why You Should Add ANRO Stock to Your Portfolio Now
ANRO

Alto Neuroscience Announces Participation in Upcoming Investor Conferences
Alto Neuroscience Announces Participation in Upcoming Investor Conferences
ANRO

Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
Alto Neuroscience Promotes Nick Smith to President and Chief Financial Officer
ANRO

Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Alto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business Highlights
ANRO

Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
Alto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common Stock
ANRO

Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
ANRO

ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point
ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point
ANRO

ANRO Stock Falls After Hours On Failed Schizophrenia Study Results
ANRO Stock Falls After Hours On Failed Schizophrenia Study Results
ANRO

Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
Are These 4 Biotech Stocks Set to Beat Q3 Earnings Estimates?
ANRO
News tone: automated (AI) classification of the article's content, not a price prediction.
About Alto Neuroscience Inc.
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individual's neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-207, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Amit Etkin M.D., Ph.D. | Founder, CEO & Chairman of the Board | 1977 |
| Mr. Nicholas C. Smith | CFO & President | 1989 |
| Mr. Michael C. Hanley M.B.A. | Chief Operating Officer | 1974 |
| Mr. Dan Segal B.Sc. (Hons), BCom, CA, MSc | Co-Founder & Strategic Advisor | 1962 |
| Ms. Erin R. McQuade J.D. | General Counsel, Chief Administrative Officer & Corporate Secretary | 1975 |
| Mr. Adam Savitz M.D., Ph.D. | Chief Medical Officer | 1966 |
| Ms. Jessica Powell | Chief Development Officer | 1975 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 71.06
- MACD 12/26/9
- 0.56
- EMA 9 of MACD
- -0.55
- MACD histogram
- 1.11
- SMA 50
- $26.62
- Price above SMA 50
- EMA 50
- $25.88
- Price above EMA 50
- SMA 200
- $24.59
- Price above SMA 200
- EMA 200
- $23.60
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $37.00
- Average
- $48.50
- High
- $60.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +8.0 | +8.5 | +29.7 | -27.5 | -10.7 | +40.4 |



